enVVeno Medical Q3 2026 net loss narrows to $4.4 million

Bitget2026/10/30 12:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

enVVeno Medical’s third-quarter 2026 net loss narrowed year over year to $4.4 million.
Operating expenses fell 8% year over year to $4.5 million.
Quarter-end cash and investments totaled $18.5 million, expected to fund operations into the fourth quarter of 2027.
The FDA-approved TAVVE pivotal study remains on track to enroll its first patient before year-end 2026.
Quarterly cash burn totaled $3 million, with $4 million to $5 million expected in the first half of 2027 during continued TAVVE enrollment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enVVeno Medical Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610300830ACCESSWRNAPR_____1244058) on October 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

enVVeno Medical Q3 2026 net loss narrows to $4.4 million

You may also like

Crypto prices